Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical ...

A decade after bringing Transcatheter Aortic Valve Replacement (TAVR) to Alaska, doctors at Providence Alaska Medical Center ...

Patients with severe aortic stenosis had comparable rates of death or disabling stroke, but the lead investigator cautions ...

A device designed to remove embolic material-fragments of tissue that can be released into the bloodstream during ...

Medtronic, Abbott and Boston Scientific provided updates on their devices used in heart valve disease treatment at the event.

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of ...

Researchers found that at five years, patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke.

Results from the EARLY TAVR trial — the first randomized, controlled FDA pivotal study designed to determine the best ...

Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its ...

Counterintuitively, use of cerebral embolic protection failed to reduce the incidence of stroke in the 72 hours following a transcatheter aortic valve replacement or implantation found a late-breaking ...